Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000117 · ClinicalTrials.gov registry record · Phase 3
Intravenous Immunoglobulin Therapy in Optic Neuritis
A Phase 3 study, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00000117: Completed Phase 3 study, sponsored by National Eye Institute (NEI).
NCT00000117 is a Phase 3 study that has completed, run by National Eye Institute (NEI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000117, a Phase 3 study, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).
Interventions
- DRUG Immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-08 |
| Est. Completion | 1997-12 |
| Phase | Phase 3 |
What the finished NCT00000117 record still lists
NCT00000117 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Immunoglobulin is the first listed.
NCT00000117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000117 about?
NCT00000117 is a clinical study titled "Intravenous Immunoglobulin Therapy in Optic Neuritis". To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement oc...
What is the current status of trial NCT00000117?
This trial is currently completed. It is a Phase 3 study. The study started on 1995-08. Estimated completion is 1997-12.
What interventions are being tested in trial NCT00000117?
The interventions under investigation include: Immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT00000117?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia